<em>Nature&nbsp;</em>Retracts Paper on Delivery System for CAR T Immunotherapy
Nature Retracts Paper on Delivery System for CAR T Immunotherapy
The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.
Nature Retracts Paper on Delivery System for CAR T Immunotherapy
Nature Retracts Paper on Delivery System for CAR T Immunotherapy

The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.

The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.

immunotherapy
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Catherine Offord | Jan 15, 2019
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Fecal Transplant Heals Colitis Caused by Immunotherapy
Fecal Transplant Heals Colitis Caused by Immunotherapy
Anna Azvolinsky | Nov 12, 2018
A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.
Drug Cocktail Slows Progress of Aggressive Breast Cancer
Drug Cocktail Slows Progress of Aggressive Breast Cancer
Ashley P. Taylor | Oct 22, 2018
Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.
James Allison and Tasuku Honjo Win Nobel Prize
James Allison and Tasuku Honjo Win Nobel Prize
Ashley Yeager, Kerry Grens | Oct 1, 2018
The immunologists, honored with the 2018 award in Physiology or Medicine, pioneered immunotherapy, which harnesses the body’s immune system to fight cancer.
Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
The Scientist Staff | Aug 22, 2018
Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.
Opinion: Learning from Immunotherapy&rsquo;s Recent Failures
Opinion: Learning from Immunotherapy’s Recent Failures
Luis Felipe Campesato | Aug 1, 2018
The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.